Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

·1 min read

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021. A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:

Company Contact:



Joyce Allaire

Dan Chevallard

LifeSci Advisors

Chief Financial Officer

jallaire@lifesciadvisors.com

dchevallard@viracta.com

(212) 915-2569

(858) 771-4193

Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-participate-at-hc-wainwright-global-life-sciences-conference-301239433.html

SOURCE Viracta